|
gptkbp:instanceOf
|
gptkb:drug
gptkb:gonadotropin-releasing_hormone_receptor_antagonist
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BX07
|
|
gptkbp:brand
|
gptkb:Orgovyx
gptkb:Relumina
|
|
gptkbp:CASNumber
|
737789-87-6
|
|
gptkbp:chemicalFormula
|
C29H27F2N7O5
|
|
gptkbp:developer
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Myovant_Sciences
|
|
gptkbp:eliminationHalfLife
|
36-65 hours
|
|
gptkbp:KEGGID
|
D10813
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
suppresses production of testosterone and estrogen
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
CHEMBL2103887
46216313
DB15181
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fatigue
increased risk of blood clots
hot flashes
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
prostate cancer
endometriosis
uterine fibroids
|
|
gptkbp:bfsParent
|
gptkb:Myovant_Sciences
gptkb:ROIV
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Relugolix
|